(Q34225659)

31 July 2017

2 references

22 August 2022

25 October 2022

Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine (English)

1 reference

31 July 2017

1 reference

Marc H V Van Regenmortel

series ordinal

1

1 reference

31 July 2017

publication date

20 October 2011

1 reference

31 July 2017

1 January 2012

2 references

22 August 2022

25 October 2022

3 references

31 July 2017

22 August 2022

25 October 2022

157

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

1-20

1 reference

https://scigraph.springernature.com/pub.10.1007/s00705-011-1145-2

31 July 2017

exact match

0 references

cites work

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Identifying epitopes of HIV-1 that induce protective antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Toward an antibody-based HIV-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

gp120: Biologic aspects of structural features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

HIV-1 neutralization: mechanisms and relevance to vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Humoral immunity to HIV-1: neutralisation and antibody effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Specificities of broadly neutralizing anti-HIV-1 sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antibodies, viruses and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Scaffolding to build a rational vaccine design strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Challenges for structure-based HIV vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Limitations to the structure-based design of HIV-1 vaccine immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

A proposal for the nomenclature of antigenic sites in peptides and proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Continuous and discontinuous protein antigenic determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Molecular recognition in antibody-antigen complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Epitopes on protein antigens: misconceptions and realities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

What is a B-cell epitope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immune epitope database analysis resource (IEDB-AR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antigenicity and native structure of globular proteins: low frequency of peptide reactive antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Adsorption of the protein antigen myoglobin affects the binding of conformation-specific monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Structural Comparison of Different Antibodies Interacting with Parvovirus Capsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antibody neutralization of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

A priori delineation of a peptide which mimics a discontinuous antigenic determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Complementarity of peptides specified by 'sense' and 'antisense' strands of DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Making sense from antisense: a review of experimental data and developing ideas on sense--antisense peptide recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Characterization of murine coronavirus neutralization epitopes with phage-displayed peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Crystal structure of a cross-reaction complex between Fab F9.13.7 and guinea fowl lysozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Identification of hepatitis A virus mimotopes by phage display, antigenicity and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Identification of the core residues of the epitope of a monoclonal antibody raised against glycoprotein D of herpes simplex virus type 1 by screening of a random peptide library

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Identification of HIV vaccine candidate peptides by screening random phage epitope libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

A new concept of immune specificity emerges from a consideration of the self-nonself discrimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Degeneracy, mimicry and crossreactivity in immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antigen-receptor degeneracy and immunological paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immunological specificity, unique combinations of selected natural globulins provide an alternative to the classical concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antibody multispecificity mediated by conformational diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Flexibility and molecular recognition in the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

From interception to incorporation: degeneracy and promiscuous recognition as precursors of a paradigm shift in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Polyspecificity of T cell and B cell receptor recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Degeneracy and complexity in biological systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Protein recognition of adenylate: an example of a fuzzy recognition template

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Pitfalls of reductionism in the design of peptide-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The fuzzy revolution: goodbye to the Aristotelian Weltanschauung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Beyond self and nonself: fuzzy recognition of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Simplicity belies a complex system: a response to the minimal model of immunity of Langman and Cohn

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

T Cell Tolerance Based on Avidity Thresholds Rather Than Complete Deletion Allows Maintenance of Maximal Repertoire Diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Kinetic and affinity limits on antibodies produced during immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Mapping epitopes on the insulin molecule using monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The antigenic structure of proteins: a reappraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Intrinsic and extrinsic factors in protein antigenic structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Structural definition of a conserved neutralization epitope on HIV-1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Theoretical considerations of the ability of monoclonal antibodies to detect antigenic differences between closely related variants, with particular reference to heterospecific reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Serological studies on naturally occurring strains and chemically induced mutants of tobacco mosaic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Specificity and degeneracy in antigen recognition: yin and yang in the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The antiviral activity of antibodies in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Neutralization of animal virus infectivity by antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Early events in B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Structural evidence for induced fit as a mechanism for antibody-antigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antibody-antigen interactions: new structures and new conformational changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Conformational changes associated with protein-protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Current status of short synthetic peptides as vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Amino and carboxy-terminal regions in globular proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Correlation between segmental mobility and the location of antigenic determinants in proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The atomic mobility component of protein antigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Production and use of antibodies against synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Benchmarking B cell epitope prediction: underperformance of existing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Chemical basis of antigenic variation in foot-and-mouth disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Conserved structural elements in the V3 crown of HIV-1 gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Structural comparison between retro-inverso and parent peptides: molecular basis for the biological activity of a retro-inverso analogue of the immunodominant fragment of VP1 coat protein from foot-and-mouth disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Protection of swine from foot-and-mouth disease with one dose of an all-D retro peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The role of antibodies in HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Deceptive imprinting and immune refocusing in vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Diversity considerations in HIV-1 vaccine selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Convergent peptide libraries, or mixotopes, to elicit or to identify specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The rational design of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Induction of immunity to human immunodeficiency virus type-1 by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Reverse vaccinology: developing vaccines in the era of genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

The rational design of biological complexity: a deceptive metaphor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Reductionism and the search for structure-function relationships in antibody molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

AIDS/HIV. A boost for HIV vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Directed evolution: the 'rational' basis for 'irrational' design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Rational dissection of binding surfaces for mimicking of discontinuous antigenic sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Herpes simplex virus vaccines--why don't antibodies protect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

A therapeutic dendritic cell-based vaccine for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Policy rebuttal. HIV vaccine trial justified.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Support for the RV144 HIV vaccine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Immunology and the elusive AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00705-011-1145-2

Comparison of different methods for localizing antigenic regions in histone H2A

21 January 2018

1 reference

12 December 2020

HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D

1 reference

12 December 2020

Binding to native proteins by antipeptide monoclonal antibodies.

1 reference

12 December 2020

Antigen specificity and cross-reactivity of monoclonal anti-lysozyme antibodies

1 reference

12 December 2020

A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

1 reference

12 December 2020

Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization

1 reference

12 December 2020

Immunological speculations

1 reference

12 December 2020

Outstanding questions on HIV vaccine trial

1 reference

12 December 2020

The concepts of crossreactivity and specificity in immunology

1 reference

12 December 2020

Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans

1 reference

12 December 2020

Degeneracy of antibody specificity

1 reference

12 December 2020

Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects

1 reference

12 December 2020

Importance of hydropathic complementarity for the binding of the neuropeptide substance P to a monoclonal antibody: equilibrium and kinetic studies

1 reference

12 December 2020

The chemistry and mechanism of antibody binding to protein antigens.

1 reference

12 December 2020

Predicting antigenic determinants in proteins: looking for unidimensional solutions to a three-dimensional problem?

1 reference

12 December 2020

Dual binding specificities in MOPC 384 and 870 murine myeloma immunoglobulins

1 reference

12 December 2020

From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites

1 reference

12 December 2020

Diverse binding site structures revealed in homology models of polyreactive immunoglobulins

1 reference

12 December 2020

Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response

1 reference

12 December 2020

Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines

1 reference

12 December 2020

Monoclonal antibodies as probes of the antigenic structure of tobacco mosaic virus

1 reference

12 December 2020

The conformational specificity of viral epitopes

1 reference

12 December 2020

Antigen recognition by conformational selection

1 reference

12 December 2020

1 reference

12 December 2020

Synthetic peptides as diagnostic tools in virology.

1 reference

12 December 2020

Antibodies of Predetermined Specificity in Biology and Medicine

1 reference

12 December 2020

Two meanings of reverse vaccinology and the empirical nature of vaccine science

1 reference

12 December 2020

On the existence of heterospecific antibodies in sera from rabbits immunized against tobacco mosaic virus determinants

1 reference

12 December 2020

Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera.

1 reference

12 December 2020

Antigenic cross-reactivity potential of synthetic peptides immobilized on polyethylene rods

1 reference

12 December 2020

Deceptive imprinting: a cosmopolitan strategy for complicating vaccination

1 reference

12 December 2020

Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus.

1 reference

12 December 2020

Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains

1 reference

12 December 2020

Cognitive features of continuous antigenic determinants

1 reference

12 December 2020

A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response

1 reference

12 December 2020

Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody

1 reference

12 December 2020

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

1 reference

12 December 2020

Virology. Moving forward in HIV vaccine development

1 reference

12 December 2020

Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies

1 reference

12 December 2020

Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization

1 reference

12 December 2020

Retrospective: 12 years of antigenic determinant predictions, and more

1 reference

12 December 2020

Molecular recognition by induced fit: how fit is the concept?

1 reference

12 December 2020

The specificity of immunological reactions

1 reference

12 December 2020

HIV-1 vaccines and adaptive trial designs

1 reference

12 December 2020

Different views of protein antigenicity

1 reference

12 December 2020

First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

1 reference

12 December 2020

Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization

1 reference

12 December 2020

Immunoinformatics may lead to a reappraisal of the nature of B cell epitopes and of the feasibility of synthetic peptide vaccines

1 reference

12 December 2020

10.1007/S00705-011-1145-2

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1042876468

0 references

PMC publication ID

7087187

0 references

1 reference